pfizer - Search News

News

Pfizer Raises Profit Outlook

Bloomberg on MSN · 1h

Pfizer Lifts Profit View as Cuts Offset Flat Sales Outlook

Pfizer Inc. raised its profit forecast for the year, with the drugmaker’s ongoing cost cuts helping to make up for a lack of expected sales growth.The company’s stock rose as much as 5.4% in New York Tuesday as investors look for good news after a decline in demand for the company’s Covid products forced the drugmaker to reshape its business.

The Wall Street Journal on MSN · 3h

Pfizer Raises Profit Outlook as Uncertainty Lingers Over Tariffs, Drug Prices

Chief Executive Albert Bourla told analysts he is hopeful about finding a solution in response to President Trump’s demands.

Reuters on MSN · 6h

Pfizer raises 2025 profit forecast as cost-cutting program gains traction

Pfizer raised its full-year profit forecast on Tuesday while reporting second-quarter results that topped Wall Street estimates, and said it expects to benefit from cost-cutting and a weaker dollar.

Pfizer, Q2

Pfizer beats in Q2 earnings, reaffirms 2025 outlook

Pfizer ( PFE) reported a beat in second quarter earnings Tuesday, and reaffirmed its 2025 guidance of between $61 to $64 billion in revenues. The company reported revenues of $14.7 billion, compared to Wall Street expectations of $13.5 billion, and earnings per share of $0.78, versus estimates of $0.58 per share.

Houston Chronicle · 8h

Pfizer: Q2 Earnings Snapshot

The average estimate of six analysts surveyed by Zacks Investment Research was for earnings of 58 cents per share. The drugmaker posted revenue of $14.65 billion in the period, also topping Street forecasts.

Zacks.com on MSN · 6h

Pfizer (PFE) Surpasses Q2 Earnings and Revenue Estimates

Pfizer (PFE) came out with quarterly earnings of $0.78 per share, beating the Zacks Consensus Estimate of $0.58 per share. This compares to earnings of $0.6 per share a year ago. These figures are adjusted for non-recurring items.

5h

Buy Pfizer Stock At $24?

Investor sentiment has been adversely affected by worries regarding the company’s drug pipeline. Nonetheless, we believe PFE ...

Fierce Pharma3h

Pfizer CEO touts 'extremely productive' talks with Trump administration as MFN pricing, tariff threats close in

As investors and industry watchers juggle the twin possibilities of pharmaceutical import tariffs and potential drug pricing ...

1h

Pharma prepared to work with Trump on DTC drug sales: Pfizer CEO

Pfizer's Albert Bourla told investors that major drugmakers are "ready to roll up their sleeves" and build out more direct-to ...

Schaeffer's Investment Research3h

Pfizer Stock Pops on Q2 Beat-and-Raise

Pfizer (PFE) stock is rising after the company reported strong second-quarter earnings and lifted its full-year forecast ...

Pfizer CEO in Touch With President Over Most Favored Nation Drug Pricing

Albert Bourla confirmed that he called President Donald Trump after receiving a letter asking Pfizer and a clutch of other ...

1h

Palantir still surging, Pfizer pops, Fox's new streaming platform

Yahoo Finance's John Hyland tracks Tuesday's top moving stocks and biggest market stories in this Market Minute. Palantir ...

1hon MSN

Pfizer Stock Rises as Earnings Smash Expectations. But These Challenges Remain.

Pfizer stock rose after the drugmaker posted adjusted earnings came in at 78 cents a share on revenue of $14.7 billion, ...

Fierce Biotech6h

Pfizer's embattled obesity program loses another GLP-1 drug

Pfizer has abanonded yet another GLP-1 drug from its shrinking obesity pipeline, as well as dumping a Clostridium difficile ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results